ERBB2 and breast carcinoma: Real-time quantitative PCR analysis showed that expression of PHLDA2 was repressed to 43.5 ± 10.6% (mean ± SD) of lapatinib-treated as compared to DMSO-treated control cells in the ErbB2-positive SkBr3 breast cancer cell line, 31.7 ± 7.2% (mean ± SD) of lapatinib-treated versus DMSO-treated control cells in ErbB2-amplified Calu-3 lung adenocarcinoma cells, 19.2 ± 3.83% of Erlotinib treated versus DMSO-treated control cell in EGFR-mutated HCC827 and 29.4 ± 2.9% of CL-387, 785-treated versus DMSO-treated control cells in EGFR-mutated H1975 lung adenocarcinoma cells (Figure 1A).